| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Acitazanolast (MTCC, WP-871), active metabolite of tazanolast, is an anti-allergic drug candidate. Aerosol WP871 (0.01 and 0.033%) inhibited the antigen-induced bronchoconstriction to some extent in a dose-dependent fashion, but high-dose WP871 (0.1%) inhalation itself produced a non-specific bronchoconstriction. Aerosol WP871 does not antagonize SRS-A, but inhibits synthesis and/or release of SRS-A and has some non-specific bronchoconstrictive effect in high concentration.
| References |
Kamei C, Mio M, Yoshida T, Saito Y, Toyoda Y, Tsuriya Y. Effect of an active
metabolite of the antiallergic agent tazanolast on histamine release from rat
mast cells. Arzneimittelforschung. 1997 Apr;47(4):390-4. PubMed PMID: 9150859.
|
|---|---|
| Additional Infomation |
Acitazanolast is a member of tetrazoles.
|
| Molecular Formula |
C9H7N5O3
|
|---|---|
| Molecular Weight |
233.18358
|
| Exact Mass |
233.054
|
| CAS # |
114607-46-4
|
| PubChem CID |
2006
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Index of Refraction |
1.719
|
| LogP |
0.29
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
311
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC(=C1)NC(=O)C(=O)O)C2=NNN=N2
|
| InChi Key |
VWQZJJZGISNFOE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H7N5O3/c15-8(9(16)17)10-6-3-1-2-5(4-6)7-11-13-14-12-
|
| Chemical Name |
Oxo-((3-(1H-tetrazol-5-yl)phenyl)amino)acetic acid
|
| Synonyms |
MTCC WP-871 WP 871 WP871.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~35.71 mg/mL (~153.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.92 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2885 mL | 21.4427 mL | 42.8853 mL | |
| 5 mM | 0.8577 mL | 4.2885 mL | 8.5771 mL | |
| 10 mM | 0.4289 mL | 2.1443 mL | 4.2885 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02176889 | Completed | Dietary Supplement: Lactospore | Healthy | KGK Science Inc. | June 2014 | Phase 1 |
| NCT02783300 | Completed | Drug: GSK3326595 Drug: Pembrolizumab |
Neoplasms | GlaxoSmithKline | August 30, 2016 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA